Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19
Sign Up to like & getrecommendations! Published in 2022 at "Viruses"
DOI: 10.3390/v14112514
Abstract: Introduction: Molnupiravir and Nirmatrelvir/r (NMV-r) have been proven to reduce severe Coronavirus Disease 2019 (COVID-19) in unvaccinated high-risk individuals. Data regarding their impact in fully vaccinated vulnerable subjects with mild-to-moderate COVID-19 are still limited, particularly… read more here.
Keywords: early access; composite outcome; high risk; risk outpatients ... See more keywords